MYOV News and Press, Myovant Sciences Ltd. From 12/20/19

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

How good are the company's cost analysis and accounting controls? - Philip Fisher For most of 2019, the China Trade War and drug pricing concerns clobbered many fundamentally strong stocks. In the thick of these market clouds, a downpour of negative sentiments washed away the market cap ...

Myovant Sciences (NYSE: MYOV ) is up 3.6% in first action since disclosing in a filing that Roivant Sciences agreed to buy 3.5M shares of Myovant from Millennium Pharma. More news on: Myovant Sciences Ltd., Healthcare stocks news, Stocks on the move, Read more ...

Gainers:  Paringa Resources (NASDAQ: PNRL ) +250% . More news on: Paringa Resources Limited, ASLAN Pharmaceuticals Limited, Hepion Pharmaceuticals, Inc., Stocks on the move, Read more ...

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. - Phillip Fisher In bioscience investing, a fundamentally-sound stock can t...

A number of biotech stocks have made major moves over the past week. One of those was Myovant Sciences (NYSE: MYOV) , a $1.1 billion biopharma company, which had its shares more than double on Nov. 19 following  impressive clinical trial results in treating early, androgen-sensitiv...

Englishmen were rained on too often to come up with anything that imaginative ." - Natasha Pulley, The Watchmaker of Filigree Street Today, we revisit Myovant Sciences (MYOV). The stock has a nice run since we took an in-depth look at it in late July and gave a 'thumbs up' to a 'watch...

BASEL, Switzerland, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Everco...